Diabetic nephropathy
Conditions
Interventions
Tangshenweining group:Tangshenweining formula + valsartan
Control group:Placebo + Valsartan
Sponsors
Beijing Chaoyang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Early DN patients; 2. Conform to the diagnosis of qi and yin deficiency and blood stasis syndrome in traditional Chinese medicine; 3. Age 18-60 years old, gender, nationality is not limited; 4. Blood pressure >= 120 / 70mmHg; 5. Fasting blood glucose <= 9mmol / L, glycosylated hemoglobin <= 8 %.
Exclusion criteria
Exclusion criteria: 1. In the past 3 months, ACEI / ARB drugs or traditional Chinese medicine for the treatment of DN were used; 2. History of primary kidney disease and secondary kidney disease except DN; 3. Urinary tract infection in the past 1 month; vaginitis or prostatitis; acute complications of diabetes, such as diabetic ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis, etc.; 4. Aminotransferase >= 2 times the upper limit of normal, or serum creatinine >= 135 µmol / L; 5. Renal artery stenosis; 6. Serious diseases of other systems; 7. Patients who combined with other traditional Chinese medicine or participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary albumin creatinine ratio, UACR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Creatinine;TCM syndrome score;vascular endothelial function;Renal hemodynamics; | — |
Countries
China
Contacts
Public ContactFeng Xiaomeng
Beijing Chaoyang Hospital, Capital Medical University
Outcome results
None listed